In vitro evaluation of CAR-T cells in patient-derived glioblastoma models

Benjamin A Brakel; Chirayu R Chokshi; Sabra K Salim; Chitra Venugopal; Sheila Singh

doi:10.1016/j.xpro.2021.100920

In vitro evaluation of CAR-T cells in patient-derived glioblastoma models

STAR Protoc. 2021 Oct 29;2(4):100920. doi: 10.1016/j.xpro.2021.100920. eCollection 2021 Dec 17.

Authors

Benjamin A Brakel¹, Chirayu R Chokshi¹, Sabra K Salim¹, Chitra Venugopal², Sheila Singh^{1

2}

Affiliations

¹ Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, ON L8S 4L8, Canada.
² Department of Surgery, McMaster University, Hamilton, ON L8S 4L8, Canada.

Abstract

Advances in chimeric antigen receptor (CAR) T cell therapies have led to the modality dominating translational cancer research; however, a standardized protocol for evaluating such therapies in vitro is needed. This protocol details the in vitro preclinical evaluation of CAR-T cell therapies for glioblastoma (GBM), including target cell cytotoxicity and T cell proliferation, activation, and cytokine release assays. For complete details on the use and execution of this protocol, please refer to Vora et al. (2020).

Keywords: Cancer; Cell culture; Cell separation/fractionation; Cell-based Assays; Flow Cytometry/Mass Cytometry; Health Sciences; Immunology.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Brain Neoplasms* / pathology
Brain Neoplasms* / therapy
Coculture Techniques / methods*
Glioblastoma* / pathology
Glioblastoma* / therapy
Humans
Immunotherapy, Adoptive*
Models, Biological*
Receptors, Chimeric Antigen / immunology
T-Lymphocytes / cytology
T-Lymphocytes / immunology
Tumor Cells, Cultured

Substances

Receptors, Chimeric Antigen